- Home
- EQS vs LYRA Comparison
EQS vs LYRA Comparison
Compare EQS & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- LYRA
- Stock Information
- Founded
- EQS 1991
- LYRA 2005
- Country
- EQS United States
- LYRA United States
- Employees
- EQS N/A
- LYRA N/A
- Industry
- EQS Finance Companies
- LYRA Medical/Dental Instruments
- Sector
- EQS Finance
- LYRA Health Care
- Exchange
- EQS Nasdaq
- LYRA Nasdaq
- Market Cap
- EQS 18.5M
- LYRA 15.0M
- IPO Year
- EQS N/A
- LYRA 2020
- Fundamental
- Price
- EQS $1.36
- LYRA $8.84
- Analyst Decision
- EQS
- LYRA Buy
- Analyst Count
- EQS 0
- LYRA 2
- Target Price
- EQS N/A
- LYRA $16.00
- AVG Volume (30 Days)
- EQS 14.8K
- LYRA 1.9M
- Earning Date
- EQS 01-01-0001
- LYRA 08-13-2025
- Dividend Yield
- EQS N/A
- LYRA N/A
- EPS Growth
- EQS N/A
- LYRA N/A
- EPS
- EQS N/A
- LYRA N/A
- Revenue
- EQS $1,329,000.00
- LYRA $1,185,000.00
- Revenue This Year
- EQS N/A
- LYRA N/A
- Revenue Next Year
- EQS N/A
- LYRA $1,286.17
- P/E Ratio
- EQS N/A
- LYRA N/A
- Revenue Growth
- EQS 152.66
- LYRA N/A
- 52 Week Low
- EQS $0.74
- LYRA $3.81
- 52 Week High
- EQS $1.52
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- EQS 67.89
- LYRA 45.31
- Support Level
- EQS $1.30
- LYRA $10.15
- Resistance Level
- EQS $1.39
- LYRA $14.88
- Average True Range (ATR)
- EQS 0.05
- LYRA 2.03
- MACD
- EQS -0.00
- LYRA -0.67
- Stochastic Oscillator
- EQS 94.74
- LYRA 0.42
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.